Revisiting methylprednisolone aceponate: efficacy, safety and current positioning
Drugs in Context · 23.07.2026 · 1
DOI: 10.7573/dic.2026-5-9 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drugs in Context, online erschienen am 23.07.2026. Verfasst von Jaime Piquero-Casals und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Aesthetic Dermatology and Laser, Dermacentric Health & Aesthetics, Barcelona, Spain. Die Arbeit nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Topical corticosteroids are essential for the management of inflammatory skin diseases but optimizing efficacy whilst minimizing adverse effects remains critical. Methylprednisolone aceponate (MPA) is a fourth-generation, non-halogenated corticosteroid developed to enhance local activity with limited systemic exposure. This review summarizes its pharmacology, clinical efficacy and safety.
Methods
A PubMed search (1990–2025) was conducted to identify relevant studies on MPA in inflammatory dermatoses.
Results
MPA’s di-esterified structure and 6α-methyl modification provide potent anti-inflammatory activity with low atrophogenic potential. It is activated within the skin to a highly active metabolite and rapidly inactivated systemically, resulting in minimal systemic absorption. Clinically, MPA provides rapid pruritus relief and high clearance rates in eczematous conditions, including atopic, contact and seborrheic dermatitis. Once-daily application is generally sufficient, supporting adherence. Its availability in multiple formulations allows treatment to be tailored to lesion type and anatomical site. Longterm use is associated with a low risk of skin atrophy or hypothalamic–pituitary–adrenal axis suppression, and allergic sensitization is rare.
Conclusions
MPA offers an effective and well-tolerated option for acute and maintenance management of inflammatory skin diseases. Download the Plain Language Summary of this article: https://www.drugsincontext.com/plain-language-summaries/plain-language-summary-revisiting-methylprednisolone-aceponate-efficacy-safety-and-current-positioning
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Aesthetic Dermatology and Laser, Dermacentric Health & Aesthetics, Barcelona, Spain.
- Hospital Universitario La Paz, Madrid, Spain.
- Department of Dermatology, Hospital Son Llàtzer, Palma de Mallorca, Spain.
- Department of Dermatology, Hospital San Pablo, Coquimbo, Chile.
- Innovation and Development, ISDIN, Barcelona, Spain.
- Department of Dermatology, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain.
ORCID-Profile: Jaime Piquero-Casals, Raul De Lucas, Juan Francisco Mir-Bonafé, Eduardo Rozas-Muñoz, Sang-Chie Lin, Anthony Brown, Ludmila Prudkin, Mónica Foyaca, Daniel Morgado-Carrasco, Vicente Garcia-Patos Briones
Zitieren
APA
Piquero-Casals, J., De Lucas, R., Mir-Bonafé, J. F., Rozas-Muñoz, E., Lin, S. C., Brown, A., Prudkin, L., Foyaca, M., Morgado-Carrasco, D., & Garcia-Patos Briones, V. (2026). Revisiting methylprednisolone aceponate: efficacy, safety and current positioning. Drugs in Context, 1. https://doi.org/10.7573/dic.2026-5-9
Vancouver
Piquero-Casals J, De Lucas R, Mir-Bonafé JF, Rozas-Muñoz E, Lin SC, Brown A, et al. Revisiting methylprednisolone aceponate: efficacy, safety and current positioning. Drugs in Context. 2026:1. doi:10.7573/dic.2026-5-9
BibTeX
@article{PiqueroCasals2026,
author = {Piquero-Casals, Jaime and De Lucas, Raul and Mir-Bonafé, Juan Francisco and Rozas-Muñoz, Eduardo and Lin, Sang-Chie and Brown, Anthony and Prudkin, Ludmila and Foyaca, Mónica and Morgado-Carrasco, Daniel and Garcia-Patos Briones, Vicente},
title = {Revisiting methylprednisolone aceponate: efficacy, safety and current positioning},
journal = {Drugs in Context},
year = {2026},
pages = {1},
doi = {10.7573/dic.2026-5-9}
}
EUVIMED